Background This phase 3 study further characterizes the efficacy and safety of reslizumab (a
humanized anti-IL-5 monoclonal antibody) in patients aged 12 to 75 years with asthma …

Background & Aims Guselkumab, a selective p19 interleukin-23 antagonist, is approved for
the treatment of plaque psoriasis and psoriatic arthritis. This study evaluated the efficacy and …

Background Despite the introduction of new monoclonal antibodies and oral therapies for
the treatment of ulcerative colitis, clinical remission rates remain low, underscoring the need …

Introduction Asthma with adult onset and elevated blood eosinophils is a difficult-to-treat
subgroup. This post hoc analysis evaluated reslizumab, an anti-interleukin-5 monoclonal …

Wnt/β-catenin signaling plays an important role in normal development. However, its aberrant
activation is associated with several cancers. The aim of this study is to examine the Wnt/β-…

Background An estimated 7% of patients with asthma have chronic rhinosinusitis with nasal
polyps (CRSwNP), and more than 80% have at least some radiographic evidence of …

Background Rates of enrolment in clinical trials in inflammatory bowel disease [IBD] have
decreased dramatically in recent years. This has led to delays, increased costs and failures to …

Background For patients with peanut allergy, there are currently no methods to predict who
will develop sustained unresponsiveness (SU) after oral immunotherapy (OIT). Objective …

Background & Aims The QUASAR Phase 2b Induction Study evaluated the efficacy and
safety of guselkumab, an interleukin-23p19 subunit antagonist, in patients with moderately to …

Rationale: Reslizumab is a humanized anti–IL-5 monoclonal antibody used as add-on
maintenance treatment for patients with uncontrolled eosinophilic asthma. Objectives: To predict …